- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06148207
[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain
In this clinical study, we proposed to perform [18F]BF3-BPA PET imaging in subjects with gliomas, to observe the binding ability and non-specific binding of the tracer to glioma lesions in vivo, and at the same time to evaluate the effectiveness of [18F]BF3-BPA in the diagnosis and differential diagnosis of glioma, and to evaluate the tolerability and safety of the tracer and the imaging method. The efficacy of [18F]BF3-BPA in the diagnosis and differential diagnosis of gliomas will be evaluated, as well as the tolerability and safety of this tracer and imaging method.
This study will provide a new method for in vivo imaging of gliomas and provide a clear and intuitive imaging basis for clinical diagnosis, differential diagnosis and treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yihui Guan, MD
- Phone Number: +8613764308300
- Email: guanyihui@hotmail.com
Study Locations
-
-
-
Shanghai, China, 200040
- Recruiting
- Huashan Hospital
-
Contact:
- Yihui Guan, MD
- Phone Number: +8613764308300
- Email: guanyihui@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Patients with suspicious brain gliomas:
- Patients diagnosed by the investigator, based on symptoms, course of disease, and MRI of the head, as having a suspected high- or low-grade brain glioma, scheduled for brain tumor resection, and with no contraindications to surgery;
- No prior and/or current surgery, radiotherapy, or puncture biopsy (other than treatment for symptomatic relief) for brain tumors;
- No other primary malignant tumor. 2. age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) 0-2; 4. adequate organ function:
- Platelet count >100 x 109/L;
- Urea/urea nitrogen and serum creatinine <1.5 times upper limit of normal (ULN);
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN.
5. Subjects should be fully informed of the content, process and possible risks of the test and voluntarily sign an informed consent form.
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from the study:
- Severe allergic reaction to any of the drugs or their components in this trial;
- Those who cannot tolerate or are contraindicated to undergo MRI and PET;
- Those who cannot accept or tolerate blood sample collection;
- Those who are unable to use effective contraception from the date of signing the informed consent to 3 months after the administration of the drug;
- pregnant or lactating women or those with positive blood pregnancy test results;
- Those who have participated in other interventional clinical trials prior to the date of informed consent and are within 5 half-lives of the trial drug, or are participating in other interventional clinical trials;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose group
Subjects in this group were injected intravenously with 5 ± 1 mCi [18F]BF3-BPA
|
Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
|
Experimental: High-dose group
Subjects in this group were injected intravenously with 9 ± 1 mCi [18F]BF3-BPA
|
Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete PET imaging
Time Frame: 90mins from time of injection
|
To evaluate the biodistribution characteristics (SUVmax, SUVmean) of PET imaging with different doses of [18F]BF3-BPA in brain tumor/normal brain tissues of patients with suspected gliomas, and to obtain the optimal imaging time and optimal dose of [18F]BF3-BPA PET imaging in patients with suspected gliomas.
|
90mins from time of injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fang Xie, PhD, Huashan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2023-778
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Positron Emission Tomography
-
Aarhus University HospitalCompletedPositron-Emission TomographyDenmark
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingTumor | Positron-Emission TomographyChina
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingPositron-Emission TomographyChina
-
First Affiliated Hospital of Chongqing Medical...RecruitingPositron-Emission Tomography | FAP | PSMAChina
-
The First Affiliated Hospital of Xiamen UniversityCompletedPositron-Emission Tomography | Tumor, SolidChina
-
Huashan HospitalRecruitingNeoplasms | Positron-Emission TomographyChina
-
ImaginAb, Inc.CompletedMetastatic Solid Tumors | Positron-Emission TomographyUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruitingPositron-Emission Tomography | FAP | SSTR2China
-
The First Affiliated Hospital of Xiamen UniversityCompletedPositron-Emission Tomography | Tumor, SolidChina
-
Imperial College LondonImperial College Healthcare NHS TrustCompletedPositron-Emission Tomography | Immunization Reaction
Clinical Trials on [18F]BF3-BPA Injection for PET Imaging
-
Progenics Pharmaceuticals, Inc.CompletedProstate CancerUnited States, Canada
-
Xiaohua ZhuRecruitingSolid Tumor, AdultChina
-
VA Greater Los Angeles Healthcare SystemLantheus Medical ImagingNot yet recruiting
-
MidLantic UrologyBlue Earth DiagnosticsNot yet recruiting
-
University of Alabama at BirminghamRecruitingHER2-positive Breast CancerUnited States
-
Institute for Neurodegenerative DisordersBiogenCompletedMultiple SclerosisUnited States
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR)Completed
-
Queen Mary University of LondonUnknown
-
Aposense Ltd.CompletedSolid Tumors | Brain Metastases
-
Nicole HillBlue Earth Diagnostics; Barrow Neurological FoundationRecruitingGrade III or Grade IV GliomaUnited States